Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

quarter with revenues totaling $1.2 billion, an increase of 13 percent, reflecting strong double-digit sales growth across all product categories. Driving this performance was robust growth from several products used for the treatment of hemophilia and immune disorders, including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM)] and immune globulin intravenous (IGIV), as well as solid growth from other plasma-based therapies, biosurgery products and vaccines.

Medication Delivery sales grew 8 percent in the quarter to $1.1 billion, with strong global sales of intravenous and nutritional therapies, and significant growth in international sales of anesthesia products and injectable drugs. Renal sales increased 6 percent to $558 million.

Baxter's investment in research and development of $190 million increased 19 percent in the first quarter as the company continues to advance its product pipeline across its business portfolio.

"Our strong and improving financial position reflects the continuing momentum in our business," said Robert L. Parkinson, Jr., chairman and chief executive officer. "Our favorable outlook for the full year allows us to continue to accelerate our investments in research and development programs that will improve treatment for patients, expand access to care and enhance the quality of life for people around the world."

Since the beginning of the year, Baxter has achieved a number of commercial, clinical and regulatory milestones, including:

-- U.S. Food and Drug Administration (FDA) approval of ARTISS [Fibrin

Sealant (Human)], the first and only slow-setting fibrin sealant

indicated for use in adhering skin grafts in adult and pediatric burn

patients.

-- The launch of GELFOAM (R) Plus Hemostasis Kit (absorbable gelatin

sponge, USP and human thrombin), which is indicated as a hemostatic

device for surgical procedures when c
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two ... photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas ... brain scans and is believed to be the largest brain imaging study ever, will ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ask ... to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will ... and a period of expert mentorship from a senior industry figure drawn from the ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... leader in providing automated, molecular testing solutions announced today ... Food and Drug Administration to market its INFINITI® CYP2C19 ... *17, of the CYP450 2C19 gene and is to ... the INFINITI® Analyzer.   "We are very ...
... (Nasdaq: OPTR ) is scheduled to present ... Hotel in New York City on Tuesday, November 2, ... http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) ... be accessible on the Company,s website at www.optimerpharma.com ...
... DIEGO, Oct. 26 aTyr Pharma, the physiocrine ... C equity financing led by Domain Associates.  Domain ... and Polaris Ventures, who also participated in the ... development of aTyr,s preclinical pipeline and advance physiocrine ...
Cached Biology Technology:AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay 2Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... What influence does the variation in estrogen level ... Using functional Magnetic Resonance Imaging, Jean-Claude Dreher, a ... 1), in collaboration with an American team from ... directed by Karen Berman, has identified, for the ...
... worldwide influenza pandemic caused by mutation of a bird-specific ... infectious avian strain has caused outbreaks of bird flu ... virus might also mutate to allow human-to-human transmission and ... protein, the polymerase, contribute to the ability of the ...
... by Dr. John Dick at Ontario Cancer Institute (OCI) have ... "human" leukemia stem cells. The converted cells, when transplanted ... can replicate the entire disease process from the very moment ... , Dr. Dick, Senior Scientist at OCI, the research ...
Cached Biology News:The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4A first glimpse of the influenza replication machine 2Cancer scientists create 'human' leukemia process to map how disease begins, progresses 2
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
...
...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: